This will be a randomized, multi-center, pharmacokinetics and hepatic safety trial of
EGCG with 36 total patients in 3 treatment arms. 36 women will be randomized to one of
the following groups: EGCG daily alone, EGCG daily with clomiphene citrate and EGCG daily
with letrozole. The randomization scheme will be stratified for age groups 18-29 and
30-40 and presence of uterine fibroids. The pharmacokinetics and hepatic safety of EGCG
with clomiphene citrate and letrozole are unknown. The trial conducted in women with and
without fibroids will allow comparisons between these groups. The results of this study
will be used to confirm hepatic safety for the larger multi-center FRIEND study.
